Reverse Triple Negative Immune Resistant Breast Cancer
A phase 2 trial of Trastuzumab rezetecan, SHR-A2102, Adebrelimab and Mecapegfilgrastim in Triple-negative breast cancer, run by Fudan University, now recruiting.
Overview
Reverse Triple Negative Immune Resistant Breast Cancer is a phase 2 interventional study registered as NCT05076682 by Fudan University, with 80 participants planned, started 2022-06-30 and due to reach its primary completion in 2026-12-31. Interventions recorded: Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz, SHR-A1811, SHR-A2102, SHR-1316, Mecapegfilgrastim, AK131, Theophylline. Conditions recorded: Triple-negative Breast Cancer.
Linked to the drug Mecapegfilgrastim because the registry names it among its interventions and Triple-negative breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
Shares SHR-A2102, Adebrelimab and the tag pipeline.
- TrialA Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Shares SHR-A2102, Adebrelimab and the tag pipeline.
- TrialMecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Shares Mecapegfilgrastim and the tag pipeline.
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
Shares SHR-A2102, Adebrelimab and the tag pipeline.
- TrialA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Shares SHR-A2102, Adebrelimab and the tag pipeline.
- TrialClinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Shares SHR-A2102, Adebrelimab and the tag pipeline.
- TrialA Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Triple-negative breast cancer (TNBC) and the tag pipeline.